Literature DB >> 29578511

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Huan Xu1, Xiang Wan1, Meng Gu1, Yanbo Chen1, Qiling Shi1, Qi Chen2, Zhong Wang3.   

Abstract

Benign prostatic hyperplasia (BPH) commonly occurs among elderly males. The condition causes symptoms in the lower urinary tract, thereby reducing the quality of life. BPH includes 2 major treatments: medication and surgery. Surgical treatment is often the most effective and final intervention. Holmium laser enucleation of the prostate (HoLEP), one of the most efficient surgical procedures for BPH, is conducted transurethrally. During surgery, the most important and most difficult part is to locate the surgical capsule of the prostate, which is consistent to the idea of anatomic surgery. Different skills may be needed in treating different parts of the prostate. HoLEP tends to be efficient and safe with good hemostatic properties, and able to treat bladder calculus, which may be the complications of BPH. The technique is particularly suitable for prostate of varying volumes and sizes. Indeed, HoLEP also presents certain disadvantages, such as a long learning curve and costly equipment. Regardless, this method may be the "new standard" and the excellent method for the surgical treatment of BPH.

Entities:  

Mesh:

Year:  2018        PMID: 29578511      PMCID: PMC5931447          DOI: 10.3791/56683

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  19 in total

1.  Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years.

Authors:  Peter J Gilling; Liam C Wilson; Colleen J King; Andre M Westenberg; Christopher M Frampton; Mark R Fraundorfer
Journal:  BJU Int       Date:  2011-08-23       Impact factor: 5.588

Review 2.  HoLEP has come of age.

Authors:  Michael W Vincent; Peter J Gilling
Journal:  World J Urol       Date:  2014-11-22       Impact factor: 4.226

Review 3.  EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.

Authors:  Christian Gratzke; Alexander Bachmann; Aurelien Descazeaud; Marcus J Drake; Stephan Madersbacher; Charalampos Mamoulakis; Matthias Oelke; Kari A O Tikkinen; Stavros Gravas
Journal:  Eur Urol       Date:  2015-01-19       Impact factor: 20.096

4.  Wolf Piranha Versus Lumenis VersaCut Prostate Morcellation Devices: A Prospective Randomized Trial.

Authors:  Marawan M El Tayeb; Michael S Borofsky; Jessica E Paonessa; James E Lingeman
Journal:  J Urol       Date:  2015-08-22       Impact factor: 7.450

5.  Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100 gm.:: a randomized prospective trial of 120 patients.

Authors:  Rainer M Kuntz; Karin Lehrich
Journal:  J Urol       Date:  2002-10       Impact factor: 7.450

6.  A prospective, randomized clinical trial comparing plasmakinetic resection of the prostate with holmium laser enucleation of the prostate based on a 2-year followup.

Authors:  Yan-Bo Chen; Qi Chen; Zhong Wang; Yu-Bing Peng; Li-Ming Ma; Da-Chao Zheng; Zhi-Kang Cai; Wen-Ji Li; Liang-Hong Ma
Journal:  J Urol       Date:  2012-11-20       Impact factor: 7.450

7.  Combination holmium and Nd:YAG laser ablation of the prostate: initial clinical experience.

Authors:  P J Gilling; C B Cass; A R Malcolm; M R Fraundorfer
Journal:  J Endourol       Date:  1995-04       Impact factor: 2.942

Review 8.  Enucleation techniques for benign prostate obstruction: which one and why?

Authors:  Arman Kahokehr; Peter J Gilling
Journal:  Curr Opin Urol       Date:  2014-01       Impact factor: 2.309

Review 9.  Which laser works best for benign prostatic hyperplasia?

Authors:  Arman Adam Kahokehr; Peter J Gilling
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

10.  Evaluation of noise hazard during the holmium laser enucleation of prostate.

Authors:  Huan Xu; Yan-Bo Chen; Meng Gu; Qi Chen; Zhong Wang
Journal:  BMC Urol       Date:  2017-08-31       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.